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Clinical cross-over comparison of mid-dilution hemodiafiltra-
tion using a novel dialyzer concept and post-dilution hemodi-
afiltration.
Background. Several studies have indicated that the im-
proved elimination of middle molecules by convective renal
replacement procedures might be associated with a better
outcome in end-stage renal disease (ESRD). On-line mid-
dilution hemodiafiltration (HDF) with the Nephros OLpu¯rTM
MD 190 hemodiafilter represents a novel extracorporeal renal
replacement therapy concept to increase the removal of middle
molecules.
Methods. In a prospective cross-over study in 10 ESRD pa-
tients, this technique was compared to on-line post-dilution
HDF with a conventional synthetic high-flux dialyzer, operated
at its technical limit, concerning small and middle molecular so-
lute removal. Each patient was treated 3 times for 4.0±0.4 hours
with both filters. Blood flow was 400 mL/min, substitution flow
(QS) during mid-dilution HDF 200 mL/min, and during post-
dilution HDF 100 mL/min, and effective dialysate flow of 700 –
QS mL/min. Instantaneous clearances, reduction ratios (RR),
and middle molecule mass transfer in continuously collected
dialysate were determined.
Results. While urea and creatinine clearances were signifi-
cantly lower (6.4% and 3.9%, respectively), middle molecule
removal was much more efficient in mid-dilution HDF over
the whole range of investigated proteins: compared to post-
dilution HDF, b 2-microglobulin (11.8 kD) clearance (165.8 ±
26.59 vs. 201.9 ± 20.63 mL/min; P < 0.001), RR (80.0 ± 5.4%
vs. 82.2 ± 5.7%; P < 0.001), and dialysate mass transfer (53%
higher; P < 0.001) were significantly higher. For the larger mid-
dle molecules, cystatin C (13.4 kD) and retinol-binding protein
(21.2 kD), mid-dilution HDF resulted in an even more supe-
rior performance, indicated by significantly higher values of all
investigated parameters.
Conclusion. On-line mid-dilution HDF with the Nephros
OLpu¯rTM MD 190 hemodiafilter appears to be a true techno-
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logic step ahead in terms of improved middle molecule removal.
This efficient procedure gives hope to play a role in preventing
or at least retarding dialysis-related long-term complications,
such as b 2m amyloidosis, in ESRD patients, and may contribute
to a more adequate dialysis therapy.
At present, about 90 different uremic toxins have been
identified, and this number certainly represents only a
minority of toxins that accumulate during chronic renal
failure and contribute to the uremic syndrome [1]. Ure-
mic toxins comprise a wide range of molecular weights.
With low-flux hemodialysis (HD), small non–protein-
bound solutes diffuse rapidly, and can pass easily through
low-flux membranes while retaining middle- (500–
15,000 Da) and large- (>15 kD) molecular weight
molecules, also classified as low-molecular-weight
(LMW) proteins. High-flux HD, using a more porous
high-flux membrane, allows larger molecules to pass
through the membrane. However, the quantity removed
becomes internal filtration limited.
Compared to high-flux HD, hemodiafiltration (HDF)
increases removal of LMW proteins such as b 2-
microglobulin (b 2m) by adding an enhanced convective
component to the solute mass transfer process. Post-
dilution on-line HDF, representing the most efficient
dialysis procedure in clinical routine, can achieve an
83% improvement in b 2m clearance and a 46% higher
b 2m reduction ratio when compared with high-flux HD
[2]. The efficiency of post-dilution HDF increases with
the infusion rate of substitution fluid, but becomes lim-
ited by hemoconcentration and high blood viscosity as
plasma water is continually ultrafiltered along the length
of the dialyzer hollow fibers. In an extreme case, red cell
damage, protein denaturation, and clotting of the dia-
lyzer fibers may occur [3]. Therefore, the ultrafiltration
limit is proposed to not exceed a filtration fraction of
0.5 [3].
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Fig. 1. Schematics of mid-dilution hemodi-
afiltration. Substitution fluid is reinfused be-
tween two high-flux dialyzers placed in series
resulting in a first post-dilution hemodiafiltra-
tion stage followed by a predilution hemodi-
afiltration stage.
In predilution HDF, higher infusion rates of substitu-
tion fluid are possible, which result in better blood rhe-
ology; however, this infusion mode leads to a dilution of
blood side solute concentration having the consequence
of reduced clearances when compared to post-dilution
HDF [4].
Even daily predilution hemofiltration [5] or daily post-
dilution on-line HDF at its operational limits [6] have
failed to normalize pretreatment b 2m plasma concentra-
tions, evoking the demand for more efficient treatment
procedures and the development of adsorptive devices,
such as b 2m adsorbers [7]. Simultaneous pre- and post-
dilutional infusion has shown to improve small solute
removal in hemofiltration [8–10]. This concept was intro-
duced as early as 1978 [11]. In HDF, mixed predilution
and post-dilution on-line infusion was proposed recently
[12]. However, though this technique may ensure safer
operating conditions, it does not achieve substantially
better removal of small- and large-size solutes relative
to post-dilution HDF [13].
HD with 2 dialyzers in series enhances treatment effi-
ciency considerably when compared to conventional sin-
gle dialyzer HD [14]. This filter arrangement represents
the basis for a combined post- and predilution HDF tech-
nique, named mid-dilution HDF, whereby substitution
fluid is infused after the first filter and before passage of
the blood through the second filter (Fig. 1). In this config-
uration, a post-dilution HDF stage is followed by a predi-
lution HDF stage, the effect being a high concentration
gradient in the first stage for efficient removal of small
molecules, and maximal ultrafiltration of plasma water
in both stages for efficient removal of larger molecules
by convection. Compared with post-dilution HDF, mid-
dilution HDF leads to comparable small solute clearances
in vitro while achieving about 80% higher b 2m clearance
(own unpublished data), promising more adequate dial-
ysis therapy in terms of LMW protein removal. How-
ever, mid-dilution HDF with 2 high-flux filters in series
has not become part of clinical routine due to high costs
and difficult handling problems. Therefore, making mid-
dilution HDF feasible for routine renal replacement ther-
apy would be an interesting objective.
In the present study, we introduce a new concept of
mid-dilution on-line HDF performed in a single cartridge,
the Nephros OLpu¯rTM MD 190 diafilter (Fig. 2). Major
study aims were to demonstrate the clinical feasibility of
this device and to assess its in vivo performance in a wide
molecular range, particularly removal of LMW proteins.
METHODS
The study was performed according to the guidelines
of Good Clinical Practice. Study approval was given by
the ethics committee of Montpellier University. The study
was prospective, randomized, and cross-over in nature.
Ten stable ESRD patients (mean age 57.3 ± 13.7 years;
7 male, 3 female) on regular thrice weekly post-dilution
HDF treatment were enrolled into the study after they
had given written informed consent. Underlying renal
diseases were glomerulonephritis (N = 6), nephrosclero-
sis (N = 1), hereditary dysplastic renal disease (N = 1),
Wegener’s disease (N = 1), amyloidosis (N = 1), and un-
known (N = 1). The mean duration of dialysis treatment
was 8.3 ± 7.77 years (range 15 to 258 months). The mean
postdialysis body weight was 66.3 ± 10.7 kg, and the body
mass index 23.3±4.59 kg/m2. All patients were anuric and
had well functioning native AV fistulas for blood access.
The patient’s concomitant medications were continued in
an unchanged manner, including heparinization for HDF
under study conditions.
Each patient underwent 1 study week of 3 consecutive
HDF treatments with the Nephros OLpu¯rTM MD 190
hemodiafilter (Nephros, Inc., New York, NY, USA; high-
flux polyethersulfone DIAPES HF800, 1.9 m2; Mem-
brana GmbH, Wuppertal, Germany) (Fig. 2) in mid-
dilution mode, and 1 week of 3 consecutive HDF treat-
ments with the control dialyzer Fresenius HF 80 S (high-
flux polysulfone, 1.8 m2; Fresenius Medical Care, Bad
Homburg, Germany) in post-dilution mode. The order of
the 2 different treatment periods was randomly assigned
to the patients. Between the 2 treatment periods, 1 week
of standard HDF was carried out.
HDF sessions were performed using Gambro AK 200
ULTRA monitors equipped for on-line preparation of
sterile infusion fluid (Gambro, Lund, Sweden). The HDF
treatment duration was kept constant for each individ-
ual patient, and ranged between 210 and 300 minutes.
One mid-dilution HDF session had to be discontinued
prematurely after 175 minutes due to coagulation of
the extracorporeal blood circuit. As a consequence, the
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Fig. 2. Mid-dilution hemodiafiltration in a single cartridge: the Nephros OLpu¯rTM MD 190 hemodiafilter. Using a special two-port header cap,
blood flows through the annular region of the fiber bundle (stage 1), mixes with substitution fluid at the other end, and flows in the reverse direction
through the core region of the fiber bundle (stage 2).
mean treatment duration with mid-dilution HDF was
marginally shorter as compared with post-dilution HDF
(239.8 ± 27.7 vs. 243 ± 25.3 minutes, respectively).
Blood flow (QB) and total dialysate flow (QDT) rates
were set at 400 mL/min and 700 mL/min, respectively,
and were kept constant for all study sessions. The effec-
tive dialysate flow (QD) entering the filter during HDF
was reduced by the delivered substitution rate (QS) as
a consequence of on-line substitution (QD = QDT −
QS). In mid-dilution HDF, QS was set at 200 mL/min,
while it was 100 mL/min during post-dilution HDF, re-
sulting in a different effective dialysate flow (QD) of 500
and 600 mL/min, respectively. To allow a better compar-
ison, QS was chosen near the operational limit of each
respective HDF mode, which was determined by pre-
vious in vitro testing for the MD 190 hemodiafilter. As
a consequence, a stepwise QS reduction of 20 mL/min
was planned when the transmembrane pressure indicated
on the display of the dialysis machine during both mid-
dilution and post-dilution HDF exceeded an arbitrary
maximum value of 400 mm Hg. This had to be done
once during the second half of the treatment in 6 of 30
mid-dilution sessions, and in 8 of 30 post-dilution ses-
sions. The mean resulting QS was 198.6 ± 2.2 mL/min for
mid-dilution HDF, and 98 ± 3.5 mL/min for post-dilution
HDF.
The ultrafiltration rate (QUF) of each session was set
according to individual patient’s interdialytic weight gain.
Anticoagulation was performed by unchanged adoption
of form and dosage of the previous routine hepariniza-
tion. Three patients received standard heparin as a bolus/
continuous infusion, and 7 patients received fractionated
heparin (enoxaparin; Lovenox, Aventis Pharma, Paris,
France) in a repeated bolus form.
Quantitation of treatment efficacy
Treatment efficacy was determined by measuring
reduction ratios (RR), instantaneous whole blood clear-
ances (K), and total mass removed (MTD) in continu-
ously collected dialysate. Furthermore, single pool Kt/V
(spKt/V) for urea was determined [15].
All blood samples were equilibrated for 3 hours before
centrifugation at 4g for 10 minutes. Plasma obtained was
stored at −20◦C until measurement.
RR was determined for the small solute urea (60 D)
and the LMW proteins b 2m (11.8 kD), cystatin C (CyC;
13.4 kD), and retinol-binding protein (RbP; 21.2 kD). For
this purpose, plasma concentrations were measured in
blood samples drawn from the arterial blood line before
the start (Cpre) and at the end (Cpost) of each treatment
session after reduction of the blood flow to 50 mL/min
and dialysate flow turned off for 15 seconds. RR was cal-
culated according to equation 1 [16]. For LMW proteins,
Cpost were corrected for changes in extracellular volume
[17].
RR = (1 − Cpost/Cpre) × 100 (Equation 1)
K was measured after 45 minutes for the small solutes
urea, creatinine (113 Da), and phosphate (96 Da), and for
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larger low molecular weight substances b 2m, CyC, and
RbP. Plasma concentrations were determined in blood
samples obtained from the arterial (Cart) and the venous
(Cven) blood line of the extracorporeal circuit. To allow
optimal mixture of blood and substitution fluid, the ve-
nous samples were drawn from an additional blood line
access, which was placed directly before the venous fis-
tula needle. During sampling, QUF was maintained due
to technical reasons derived from the Gambro monitors,
which interrupts the substitution flow as soon as QUF is
set at 0. Therefore, QUF was taken into account for cal-
culation of K (equation 2) [18]:
Ksolute = QB × (Cart − Cven/Cart)
+ (QUF × Cven/Cart)
(Equation 2)
For reference purposes, estimates of plasma water clear-
ances were calculated using the patient’s most recent
hematocrit level (Hct) and their predialysis total protein
level (TP, g/L) according to equation 3. To account for
the amount of solute in the red cell, solute partition co-
efficients (SPC) were assumed as 0.86 (urea), 0.73 (crea-
tinine), 0.5 (phosphate), and 0 (b 2m and CyC).
Kplasma = Ksolute × (1 − 0.00107 × TP)
×((SPC × Hct) + (1 − Hct)) (Equation 3)
MTD was determined only during the midweek sessions.
A spent dialysate fraction of 10 mL/min was collected
continuously during the whole HDF duration (t) via a T-
connector inserted into the dialysate drainage line. The
accuracy of the drainage volume, which consists of QD,
QS, and QUF, was verified during each session. In addi-
tion to the LMW protein concentrations (CLMW) of b 2m,
CyC, and RbP, the albumin (67 kD) concentration was
determined in an aliquot taken from the collected spent
dialysate. The mass in dialysate of LMW proteins was
calculated according to equation 4.
MTD= CLMW × (QD+QS+QUF) × t (Equation 4)
All LMW protein concentrations were measured by laser
immunonephelometry (BN 100 Analyzer; Dade-Behring
Marburg GmbH, Marburg, Germany). For the deter-
mination of RbP in dialysate, the samples were con-
centrated using a centrifugal filter device (Centriprep
YM-3; Millipore Corp., Bedford, MA, USA) before
measurement.
Data analysis
Descriptive analysis of the results was performed by
calculating mean values ± standard deviation (SD).
Comparative statistical analyses of within-subject within-
treatment changes from baseline and within-subject
between-treatment differences were assessed using the
two-sided paired t test. A P value of < 0.05 was consid-
ered as statistically significant. Statistical evaluation was
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Fig. 3. Comparison of small solute and LMW protein clearances at 45
minutes in mid- and post-dilution HDF. Data are mean values ± SD
(N = 30). ∗P < 0.001; ∗∗P < 0.05.
performed by means of the SAS software package (ver-
sion 8.2; Cary, NC, USA).
RESULTS
Clinical observations
All patients completed the whole study period. During
the first mid-dilution HDF treatment of 1 male patient
on a repeated bolus enoxaparin anticoagulation regimen
(6000 IU in total), the extracorporeal blood circuit coag-
ulated, and the treatment had to be stopped prematurely
after 175 minutes. This episode represented the only
adverse event during the study. Both mid-dilution and
post-dilution HDF were performed without provoking
any adverse symptoms, such as headache or hypotension,
in the patients.
Treatment efficiency
Mean whole blood instantaneous clearances are re-
ported in Figure 3. In general, post-dilution HDF led
to significantly higher small solute clearances than mid-
dilution HDF with the Nephros OLpu¯rTM MD 190
hemodiafilter. For urea and creatinine, clearances were
6.4% and 3.9% lower in mid-dilution HDF, respectively,
while no difference was found for phosphate. LMW pro-
tein clearances were substantially higher for the mid-
dilution device (Fig. 3). A 21.7% clearance increase was
found for b 2m (201.9 ± 20.63 vs. 165.8 ± 26.59 mL/min).
For the larger LMW protein CyC, the increase compared
to post-dilution HDF amounted to even 36.9% (176.4 ±
14.90 vs. 128.9 ± 14.25 mL/min). Both differences were
highly significant (P < 0.001). For RbP, negative clear-
ance values were determined in mid- and post-dilution
HDF (data not displayed).
For reference, whole blood clearances were converted
to plasma water clearances as follows. For mid-dilution
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Fig. 4. Comparison of LMW protein mass transfer into dialysate dur-
ing mid- and post-dilution HDF. Data are mean values ± SD (N = 10).
∗P < 0.001.
HDF with the MD 190 hemodiafilter, plasma water clear-
ances were 283.4 ± 10.3 (urea), 220.0 ± 14.4 (creatinine),
212.5 ± 29.2 (phosphate), 121.4 ± 11.9 (b 2m), and 104.9 ±
7.5 (CyC) compared to 302.5 ± 13.6 (urea), 228.6 ± 18.0
(creatinine), 211.5 ± 32.6 (phosphate), 99.5 ± 14.7 (b 2m),
and 73.2 ± 5.0 (CyC) mL/min for the post-dilution HDF.
Dialysate mass transfer data of LMW proteins are
given in Figure 4. As expected from clearance data, sub-
stantially enhanced LMW protein removal into dialysate
was measured in mid-dilution HDF as compared to
post-dilution HDF. Differences in dialysate mass trans-
fer, all of them highly significant, increased essentially
with larger molecular weight. Compared to post-dilution
HDF, a 53% higher mass in dialysate was determined
in mid-dilution HDF for b 2m (11.8 kD), while it was
110% higher for CyC (13.4 kD), and 390% higher for
RbP (21 kD). This trend was consistent also for albumin
(67 kD). Compared to an albumin loss of 6.32 ± 1.63 g
with the Nephros hemodiafilter, a much lower loss of only
0.42 ± 0.13 g was found in post-dilution HDF (P < 0.001).
However, corresponding to hemoconcentration due to
weight loss, rising serum albumin values in the treatment
course were noted in both mid- and post-dilution HDF
(39.2 ± 4.77 to 43.4 ± 6.1 g/L vs. 39.6 ± 3.16 to 44.8 ±
5.4 g/L, respectively; P not significant between mid- and
post-dilution HDF).
Reduction ratios of urea and LMW proteins are dis-
played in Figure 5. The higher small solute clearance
of post-dilution HDF was reflected by a higher urea re-
moval of 80.8 ± 3.1 vs. 77.3 ± 4.2%. Likewise, the es-
timated spKt/V achieved with post-dilution HDF was
1.99 ± 0.21 compared to 1.79 ± 0.21 with mid-dilution
HDF. A different pattern was demonstrated for LMW
proteins. While b 2m reduction rates were generally sim-
ilar in both HDF modes, mid-dilution HDF was signifi-
cantly higher at 82.2 ± 5.7% compared to 80.0 ± 5.4% for
post-dilution HDF (P < 0.001). Plasma removal of CyC
and RbP was also significantly enhanced in mid-dilution
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Fig. 5. Comparison of urea and LMW protein plasma reduction ratios
achieved by mid- and post-dilution HDF. Data are mean values ± SD
(N = 30). ∗P < 0.001; ∗∗P < 0.05.
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HDF with the OLpu¯rTM hemodiafilter, being 8.6% higher
for CyC and 67.2% higher for RbP.
Comparing mean pretreatment plasma b 2m before the
first and the third session (i.e., after 2 treatments only),
both mid- and post-dilution HDF reduced the level sig-
nificantly (Fig. 6). However, mid-dilution HDF led to a
significantly lower b 2m concentration compared to post-
dilution HDF (28.8 ± 7.8 to 23.4 ± 5.2 mg/L vs. 28.7 ± 7.9
to 25.6 ± 6.5 mg/L).
DISCUSSION
Post-dilution HDF is regarded as the most efficient ex-
tracorporeal renal replacement therapy available for clin-
ical routine. Efficiency of post-dilution HDF increases
with the infusion rate, but it becomes limited by hemo-
concentration along the dialyzer due to ultrafiltration
of plasma water [3]. To overcome those limits, expen-
sive technical modifications of the HDF procedure have
been proposed, which mainly target on the safety of post-
dilution HDF with only small benefits in efficiency [12,
13].
In contrast to this, on-line mid-dilution HDF with
the single cartridge Nephros OLpu¯rTM MD 190 diafilter
represents a new simple concept, which substantially en-
hances mass removal across the spectrum of LMW pro-
teins. Compared to post-dilution HDF, mid-dilution HDF
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with this device allows the infusion of much higher substi-
tution fluid volumes, thereby enhancing convective mass
transfer without diluting solutes in blood to an extent
found in predilution HDF. This last statement has been
demonstrated internally through bench studies (unpub-
lished data), whereby clearance was measured over a
broad range of substitution rates and blood flow rates.
In these bench studies, a positive linear correlation be-
tween clearance and substitution rate (QS) was observed
for urea, cytochrome C (in vitro clearance marker), and
b 2m. During simulated testing with bovine blood (QB =
400 mL/min, QD + QS = 800 mL/min), b 2m clearance
increased by 38 mL/min for each 100 mL/min increase in
substitution rate. This net increase is similar to the dif-
ference in b 2m clearance observed in our clinical study,
where 100 mL/min higher substitution fluid rate in mid-
dilution HDF resulted in a 36.1 mL/min improvement in
b 2m clearance when compared to post-dilution HDF.
The results of our study demonstrate that b 2m, as a
reference middle molecule involved in dialysis-related
amyloidosis, is by far better removed with mid-dilution
HDF as compared to post-dilution HDF, the latter per-
formed at its operational limit. While b 2m clearance was
21.7% higher, b 2m mass transfer into dialysate was 53%
higher in mid-dilution HDF. Certainly, this finding has to
be regarded with some caution because b 2m adsorption,
which can be considerably high with synthetic dialysis
membranes [19], was not taken into account. To assess
adsorption, spent dialysate samples (taken at the instan-
taneous clearance measurement time point) were ana-
lyzed for b 2m for computing mass balance error. The
mass balance error for both devices was, on average, a
negative value suggesting some adsorption of b 2m on the
membrane was occurring at this point during the treat-
ment. Though the mass balance error was slightly higher
for the control device (29% vs. 11%), it remains difficult
to draw any significant conclusions with respect to what
is happening over the entire treatment based on a single
time point determination. However, enhanced b 2m elim-
ination led only to slightly higher plasma removal rates,
which appear to be extremely high in both mid- and post-
dilution HDF when compared to literature data on HDF
[2, 6]. This finding may result from limitations in the in-
tercompartmental distribution of b 2m, which seems to
be inadequately characterized by one- or two-pool mod-
els, and has not been investigated in patients on highly
efficient HDF treatments [20, 21].
For the larger LMW proteins CyC and RbP, perfor-
mance data were consistent and indicated significantly
superior plasma removal rates and dialysate mass transfer
in mid-dilution HDF. With increasing molecular weight,
differences in treatment efficiency between mid- and
post-dilution HDF rose, being 110% higher for CyC
(13.4 kD) dialysate mass transfer, and a 389% larger
RbP (21 kD) dialysate mass transfer than that achieved
by post-dilution HDF. This more efficient removal of
LMW proteins by mid-dilution HDF opens the possi-
bility to target even larger uremic toxins, such as com-
plement factor D (24 kD), which is suspected to play
a role in the increased rate of infectious complications
in ESRD patients. Compared to high-flux hemodialysis,
post-dilution on-line HDF has already shown to reduce
factor D plasma levels significantly [22]. A further reduc-
tion can be expected from mid-dilution HDF. Even if the
design of our short study is not appropriate to draw defini-
tive conclusions, such expectations are supported by our
data, which show a significantly lower pretreatment b 2m
level before the third mid-dilution HDF when compared
to post-dilution HDF (Fig. 6).
Additional support for the need to eliminate an en-
larged spectrum of substances in order to achieve more
adequate renal replacement therapy comes from 2 recent
studies on super-flux dialyzers. Chronic hemodialysis with
these protein-leaking devices resulted in a better con-
trol of hyperhomocysteinemia, which is associated with
an increased risk for cardiovascular events in the gen-
eral population, due to a presumed removal of larger so-
lutes that influence homocysteine metabolism [23, 24].
Furthermore, super-flux hemodialysis is expected to im-
prove renal anemia control, which might be attributed to
the elimination of albumin-bound furancarboxylic acid
[25]. Like super-flux dialysis, mid-dilution HDF leads to
a not negligible albumin loss, which amounted to 6.3 g in
our study. Whether an albumin loss of such magnitude,
which is observed in peritoneal dialysis to a similar ex-
tent, can be regarded as acceptable, or even beneficial, is
controversially discussed [26]. Long-term studies to de-
fine an upper limit of albumin loss of renal replacement
therapies are lacking. Microinflammation and the closely
associated low protein intake may be more important
for the development of hypoalbuminemia than the pro-
tein loss of a particular dialysis therapy [26]. However,
ESRD patients being treated with an albumin-leaking
therapy form should be closely followed-up for symp-
toms of malnutrition, such as hypoalbuminemia and loss
of body mass.
In contrast to improved LMW protein removal, urea
and creatinine clearances, and subsequent treatment effi-
ciency measures (urea reduction ratio and spKt/V) were
significantly superior in post-dilution HDF during our
study. This finding was not surprising, although our own
in vitro experiments revealed similar small solute clear-
ances for both mid- and post-dilution HDF (unpublished
data). The explanation may come from differences be-
tween in vitro and in vivo treatment conditions. The clin-
ical study was performed with Gambro AK 200 ULTRA
on-line HDF monitors, which is limited to a maximum
dialysate flow of 700 mL/min. Compared to the clini-
cal study, our in vitro experiments were performed us-
ing identical blood and substitution fluid flows, but the
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effective dialysate flow then was 100 mL/min higher, be-
ing 600 and 700 mL/min in mid- and post-dilution HDF,
respectively, as the total dialysate flow was set at 800 mL/
min. The influence of the dialysate flow on small solute
clearance is not linearly related. Despite the same ab-
solute difference, a dialysate flow reduction from 600 to
500 mL/min leads to a higher decrease of small solute
clearance than does a reduction from 700 to 600 mL/min
[27]. Furthermore, the design of the Nephros hemodiafil-
ter is such that a cocurrent dialysate flow exists as part
of the second “predilution” stage (Fig. 2). The loss in de-
vice efficiency associated with both cocurrent dialysate
flow and predilution of blood entering the second stage
(which reduces the blood/dialysate concentration gradi-
ent that drives small solute diffusive clearance) is likely
more affected and worsened at reduced dialysate flow
rates when compared to standard HD. To achieve com-
parable small solute clearances in mid- and post-dilution
HDF, it is therefore recommended to set dialysate flows
to values of 800 mL/min, if possible. However, the dial-
ysis dose achieved by mid-dilution HDF in our study far
exceeded current dose recommendations [28].
In contrast to urea and creatinine clearances, and de-
spite being a small solute, phosphate clearances were al-
most identical in both mid- and post-dilution HDF. It
is a well-established fact that, due to a hydration shell
surrounding the phosphate molecule, phosphate rather
behaves like a middle molecular, than a small molecu-
lar, substance. Therefore, phosphate is particularly well
removed by convective dialysis procedures [29].
The first clinical application of mid-dilution HDF with
the OLpu¯rTM MD 190 hemodiafilter in 10 ESRD patients
over a short period of 1 week evidenced that this treat-
ment procedure represents a feasible, easily performed
extracorporeal renal replacement therapy. Compared to
post-dilution HDF, it was equally well tolerated without
provoking side effects in the patients. However, a single
mid-dilution HDF treatment had to be stopped prema-
turely due to a coagulated extracorporeal blood circuit
in a patient on repeated bolus enoxaparin, which was
adopted in an unchanged manner from the patient’s stan-
dard HDF protocol. It has to be assumed that the unique
design of the Nephros hemodiafilter, with its longer, com-
pared to a standard dialyzer, and turning blood pathway
(Fig. 2), may lead to a considerably higher activation of
coagulation. In fact, compared to a standard DIAPES
HF800 dialyzer, which has proven very low activation of
coagulation [30], in vitro assessment in a 1-hour sham
dialysis experiment has demonstrated a higher gener-
ation of thrombin-antithrombin-III complexes (15.6 vs.
86.4 ng/mL; N = 3), a standard biocompatibility parame-
ter to detect the activation of the coagulation cascade. On
the other hand, as presented above, mid-dilution HDF is
a more efficient convective therapy in terms of LMW
protein removal than post-dilution HDF. Given the fact
that all treatments were performed according to the rou-
tine procedures of the study center, fractionated heparin
was initially injected by a prefabricated syringe via the
arterial bloodline port when the extracorporeal circuit
was filled with blood. At that moment, anticoagulation is
incomplete and unbound middle molecular enoxaparin
(3800 Da) could have been removed by the highly effi-
cient mid-dilution HDF therapy. In this context, a recent
study, which compared on-line predilution hemofiltration
and HDF to high-flux HD, has shown that a higher con-
vective mass transfer caused by a greater ultrafiltration
volume is associated with an increased procoagulatory ac-
tivity in the extracorporeal circuit [31]. However, further
study treatments were uneventful without changing hep-
arin dosages after fractionated heparin was given in all pa-
tients before connection to the extracorporeal bloodlines.
This was to guarantee systemic anticoagulation prior to
starting the therapy.
CONCLUSION
Even if the HEMO study has failed to demonstrate
a clear advantage of high-flux dialysis over conventional
low-flux dialysis [28], convective therapies with enhanced
LMW protein removal seem to improve outcome of
ESRD patients [32]. On-line mid-dilution HDF with the
single cartridge Nephros OLpu¯rTM MD 190 hemodiafil-
ter appears to be a true technologic step ahead in terms
of improved LMW protein removal. This efficient device
gives hope to play a role in preventing, or at least retard-
ing, dialysis-related long-term complications, such as b 2m
amyloidosis, in ESRD patients. However, contribution
to a more adequate dialysis therapy with proven clinical
benefit must be demonstrated with long-term studies.
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